Patients are searching for this trial right now

This page is already ranking on Google. Activate it to start receiving pre-qualified patient leads directly in your inbox.

14-day free trial · $44/mo after · Cancel anytime · Money-back guarantee

NCT03111459 · The Christ Hospital

Repair of Thoracoabdominal Aortic Aneurysms

What this study is about

The primary objective of the clinical investigation is to assess the use of the Medtronic Valiant Thoracoabdominal Stent Graft System to repair thoracoabdominal aortic aneurysms in patients having appropriate anatomy. The primary intent of the study is to assess safety and preliminary effectiveness of the device.

View original scientific description

The primary objective of the clinical investigation is to assess the use of the Medtronic Valiant Thoracoabdominal Stent Graft System to repair thoracoabdominal aortic aneurysms in patients having appropriate anatomy. The primary intent of the study is to assess safety and preliminary effectiveness of the device. Additionally, the study will assess technical success and treatment success at each follow-up interval.

Who can participate

This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.

Inclusion criteria

  • A patient may be entered into the study if the patient has at least one of the following:
  • an aneurysm with a maximum diameter of \> 5.5 cm or 2 times the normal diameter just proximal to the aneurysm using orthogonal (i.e., perpendicular to the centerline) measurements
  • aneurysm with a history of growth \> 0.5 cm in 6 months
  • saccular aneurysm deemed at significant risk for rupture
  • symptomatic aneurysm greater than 4.5 cm
  • Axillary or brachial and iliac or femoral access vessel morphology that is compatible with vascular access techniques, devices or accessories, with or without use of a surgical conduit.
  • Proximal landing zone for the thoracic bifurcation stent graft that has:
  • ≥ 2.5 cm of nonaneurysmal aortic segment including previously placed graft material (neck) distal to the left subclavian artery (LSA) diameter in the range of 26-42 mm.
  • adequate distance from the celiac artery, in order to accommodate cannulation from the antegrade access point when considering the total deployed length of the thoracic bifurcation and visceral manifold.
  • Minimum branch vessel diameter ≥ 5 mm.
  • Iliac artery or aortic distal fixation site, including both native tissue and previously placed graft, greater than or equal to 15 mm in length and diameter in the range of 8 - 25 mm.
  • Patient is ≥ 18 years of age.
  • Patient has a life expectancy \> 1 year.

Exclusion criteria

  • Patient is a good candidate for and elects open surgical repair.
  • Patient can be treated in accordance with the instructions for use with a legally marketed endovascular prosthesis.
  • Patient is eligible for enrollment in a manufacturer-sponsored IDE at the investigational site.
  • Patient is unwilling to comply with the follow-up schedule.
  • Patient is unable or refuses to give informed consent.
  • Urgent or emergent presentation.
  • Patient is pregnant or breastfeeding.
  • Patient has a contained rupture.
  • Patient has a ruptured aneurysm.
  • Patient has a dissection in the treated portion of the aorta.
  • Obstructive stenting of any or all of the visceral vessels.
  • Poor performance status including 2 major system failures (cardiovascular, renal, hepatobiliary, neuromuscular). Medical Exclusion Criteria:
  • Patient has known sensitivities or allergies to the materials of construction of the devices, including nitinol (Nickel: Titanium), polyester, platinum-iridium, polytetrafluoroethylene (PTFE), platinum, gold, polyethylene, or stainless steel.
  • Patient has known hypersensitivity or contraindication to anticoagulation or contrast media that cannot be adequately medically managed.
  • Patient has an uncorrectable coagulopathy.
  • Patient has a body habitus that would inhibit x-ray visualization of the aorta or exceeds the safe capacity of the equipment.
  • Patient has had a major surgical or interventional procedure. unrelated to the treatment of the aneurysm planned \< 30 days of the endovascular repair.
  • Patient has unstable angina (defined as angina with a progressive increase in symptoms, new onset at rest or nocturnal angina).
  • Patient has a systemic or local infection that may increase the risk of endovascular graft infection.
  • Baseline creatinine greater than 2.0 mg/dL.
  • History of connective tissue disorders (e.g., Marfan Syndrome, Ehler's Danlos Syndrome). Anatomical Exclusion Criteria:
  • Thrombus or excessive calcification within the neck of the aneurysm.
  • Anatomy that would not allow maintenance of at least one patent hypogastric artery.
  • Anatomy that would not allow primary or assisted patency of the left subclavian artery. Expanded Selection Criteria: Subjects who fail to meet inclusion criteria for the primary study arm may be enrolled under an expanded selection arm if they meet the following criteria. Inclusion Criteria:
  • Patient that meets the criteria for inclusion in the primary study arm but has one or more of the following criteria which would exclude them from the primary study arm:
  • Patient has a minimum branch vessel diameter less than 5 mm.
  • Patients presents urgently or emergently.
  • Patient has a contained rupture.
  • Patient has a ruptured aneurysm.
  • Patient has a type B dissection (subacute or chronic) in the portion of the aorta intended to be treated.
  • Patient has poor performance status including two major system failures (cardiovascular, pulmonary, renal, hepatobiliary, and neuromuscular).
  • Patient's baseline creatinine greater than 2.0 mg/dL.
  • Patient's anatomy that would not allow for maintenance of at least one hypogastric artery.
  • Patient's anatomy that would not allow for primary or assisted patency of the left subclavian artery. Or
  • Patient that meets the criteria for inclusion in the primary study arm and:
  • Would not be eligible for the primary study arm per a documented reason other than those outlined above, and
  • Per the opinion of the Principal Investigator, with concurrence of the IRB, alternative therapies are unsatisfactory and the probable risk of using the investigational device is no greater than the probable risk from the disease or condition.

Where

  • Cincinnati, Ohio

Frequently asked questions

What is a clinical trial?

A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.

Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.

Will I be compensated?

Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.

Will I receive a placebo instead of treatment?

When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.

Can I leave a trial if I change my mind?

Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.

How long does a clinical trial last?

Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.

Data: ClinicalTrials.gov · synced Feb 8, 2024 · Source of record for eligibility and locations

📊
1 of 15 participants interested
7% interest

See if this study fits

A short prescreen based on this study's listed criteria. A coordinator confirms eligibility — this is not a medical assessment.

Preparing your pre-screening questions…

Study locations

Choose your preferred location, or select flexible during enrollment.

RECRUITING

Cincinnati

Ohio

Location available

Express your interest

Share your contact details and a study coordinator can follow up about screening.

Secure & Confidential

Your information is protected and will only be shared with the research team.

What participation can include

  • Study-related care provided by the research team
  • Close monitoring by medical professionals
  • Possible compensation for time and travel*
  • The option to withdraw at any time
  • Contributing to medical research that may help future patients

*Compensation varies by study. Confirm details with coordinator.

Typical next steps

  1. 1.Submit this form
  2. 2.Phone screening
  3. 3.In-person assessment if eligible
  4. 4.Begin participation

Find More Heart Attack Trials by City

Browse all heart attack clinical trials in these cities — not just this study.

Looking for Thoracoabdominal Aneurysm Treatment in Cincinnati?

Join others in Ohio exploring innovative treatment options through clinical research

Thoracoabdominal Aneurysm Treatment Options in Cincinnati, Ohio

If you're searching for Thoracoabdominal Aneurysm treatment in Cincinnati, participating in a clinical research study may provide access to innovative approaches under expert medical supervision. This study is actively recruiting participants in Cincinnati and surrounding areas.

Clinical trials offer participants the opportunity to receive cutting-edge treatments while contributing to medical research that may help future patients with Thoracoabdominal Aneurysm. All study-related care is provided at no cost to participants.

Local Sites
1 locations in Ohio
Now Enrolling
Up to 15 participants
Quick Start
Screening available now

Why Consider a Clinical Trial for Thoracoabdominal Aneurysm?

Potential Benefits

  • Access to new treatment approaches before public availability
  • Close monitoring by experienced medical professionals
  • Study-related care provided at no cost
  • Contribute to medical research for Thoracoabdominal Aneurysm

What to Expect

  • Initial screening to determine eligibility
  • Regular check-ups and monitoring visits
  • Possible compensation for time and travel
  • You can withdraw at any time

Frequently Asked Questions About This Thoracoabdominal Aneurysm Study

Important Clinical Trial Information

This information is provided for educational purposes and does not constitute medical advice. Clinical trial participation involves potential risks and benefits. Eligibility requirements apply and will be assessed during the screening process.

Study identifier: NCT03111459. For complete study details, visit ClinicalTrials.gov. Always consult with your healthcare provider before making decisions about your medical care or participating in clinical research.